All In Biotech

Drug Trial Radar · NCT04175600

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged >=2 to <18 Years With Pulmonary Arterial Hypertension

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

138

Actual

Start

Jan 16, 2020

Primary completion

Oct 11, 2024

Study completion Oct 1, 2027

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.

Conditions

  • Hypertension, Pulmonary

Interventions

  • SelexipagDrug

    Selexipag tablet will be administered orally.

  • PlaceboDrug

    Matching placebo tablets will be administered orally.

  • Standard of Care (SOC): Endothelin receptor antagonistDrug

    ERAs will be administered as SOC therapy.

  • SOC: Phosphodiesterase type 5 (PDE-5) inhibitorDrug

    PDE-5 inhibitor will be administered as SOC therapy.

  • SOC: Soluble guanylate cyclase stimulatorDrug

    Soluble guanylate cyclase stimulator will be administered as SOC therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double-blind Period: Time to Disease ProgressionTime frame: Placebo arm: Randomization (Day 1) up to 7 days after last dose in the DB treatment (maximum up to 199 weeks); Selexipag arm: Randomization (Day 1) up to 7 days after last dose in the DB treatment (maximum up to 213 weeks)

Locations

116 sites in 32 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • UCLA Medical Center

    Los Angeles, California

  • UCSF

    San Francisco, California

  • Childrens Hospital Colorado

    Aurora, Colorado

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Congenital Heart Center of the University of Florida

    Gainesville, Florida

  • Riley Hospital for Children

    Indianapolis, Indiana

  • Detroit Medical Center

    Detroit, Michigan

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Childrens Hospital Of Philadelphia

    Philadelphia, Pennsylvania

  • Texas Children's Hospital

    Houston, Texas

  • Primary Children's Hospital

    Salt Lake City, Utah

  • University of Virginia Division of Pediatric Cardiology

    Charlottesville, Virginia

  • Queensland CHILDREN'S HOSPITAL

    South Brisbane, Australia

  • State Institution Republican Scientific And Practical Center For Pediatric Surgery

    Minsk, Belarus

  • Health Institution 4Th City Children'S Clinical Hospital

    Minsk, Belarus

  • ULB Hôpital Erasme

    Brussels, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Universitaire Ziekenhuizen Leuven

    Leuven, Belgium

  • Complexo de Prevencao,Diagnostico,Terapia e Reabilitacao Respiratoria LTDA Hospital Dia do Pulmao

    Blumenau, Brazil

  • Fundacao Universitaria de Cardiologia - Instituto de Cardiologia e Transplantes do DF

    Brasília, Brazil

  • Hospital Pequeno Principe

    Curitiba, Brazil

  • Secretaria da Saude do Estado do Ceara - Hospital Doutor Carlos Alberto Studart Gomes

    Fortaleza, Brazil

  • Irmandade Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Brazil

  • Fundacao Universitaria de Cardiologia

    Porto Alegre, Brazil

  • Irmandade Santa Casa de Misericordia de Sao Paulo

    São Paulo, Brazil

  • SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo

    São Paulo, Brazil

  • Multiprofile Hospital For Active Treatment National Cardiology Hospital, Ead

    Sofia, Bulgaria

  • Stollery Children's Hospital

    Edmonton, Alberta, Canada

  • Hospital For Sick Children

    Toronto, Ontario, Canada

  • Beijing Anzhen Hospital

    Beijing, China

  • Guangzhou Women And Childrens Medical Center

    Guangzhou, China

  • Qingdao Women and Children's Hospital 1

    Qingdao, China

  • Qingdao Women and Children's Hospital

    Qingdao, China

  • Shanghai Childrens Medical Center

    Shanghai, China

  • Children S Hospital of Fudan University

    Shanghai, China

  • The General Hospital of Northern Theater Command

    Shenyang, China

  • Clinica San Rafael

    Bogotá, Colombia

  • Fundacion Neumologica Colombiana

    Bogotá, Colombia

  • Fundacion Santa Fe de Bogota

    Bogotá, Colombia

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.